MEK inhibition enhances bleomycin A5-induced apoptosis in an oral cancer cell line: Signaling mechanisms and therapeutic opportunities

Journal of Oral Pathology and Medicine

Volumn 33, Issue 1, 2004, Pages 37-45

  Yang, Li Chiu ^a   Yang, Shyh Hwang ^b   Tai, Kuo Wei ^a   Chou, Ming Yung ^a   Yang, Jaw Ji ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Bleomycin; Cancer therapy; ERK; JNK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; BLEOMYCIN A5; DNA FRAGMENT; DRUG DERIVATIVE; ENZYME INHIBITOR; FLAVONOID; JNK ACTIVATING PROTEIN KINASE; JNK-ACTIVATING PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PROTEIN KINASE (CALCIUM,CALMODULIN); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL DEATH; CELL NUCLEUS; CELL STRAIN KB; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUTH CANCER; MOUTH TUMOR; PATHOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ULTRASTRUCTURE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLEOMYCIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CELL SURVIVAL; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KB CELLS; MAP KINASE KINASE 4; MAP KINASE KINASE KINASE 1; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MOUTH NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0742306314     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00006.x     Document Type: Article

References (36)

1. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54.
2. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000; 407: 796-801.
3. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999; 96: 245-54.
4. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000; 407: 802-10.
5. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen activated protein kinase: conservation of a three-kinase module from yeast to human. Phys Rev 1999; 79: 143-80.
6. Cobb M, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 1995; 270: 14843-6.
7. Davis R. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
8. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180-6.
9. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signaling. Oncogene 1998; 17: 1457-62.
10. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77: 841-52.
11. Lehmann K, Janda E, Pierreux CE, et al. Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 2000; 14: 2610-22.
12. von Gise A, Lorenz P, Wellbrock C, et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 2001; 21: 2324-36.
13. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA, Chambers TC. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf 1/MEK/ERK cascade. J Biol Chem 2000; 275: 29980-5.
14. Huang Y, Hutter D, Liu Y, et al. Transforming growth factor-β1 suppresses serum deprivation-induced death of A549 cells through differential effects on c Jun and JNK activities. J Biol Chem 2000; 275: 18234-42.
15. Tournier T, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-4.
16. Avdi NJ, Nick JA, Whitlock BB, et al. Tumor necrosis factor-α activation of the c-Jun N-terminal kinase pathway in human neutrophils. J Biol Chem 2001; 276: 2189-99.
17. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97: 575-86.
18. Estus S, Zark WJ, Freeman RS, Gruda M, Bravo R, Johnson EMJ. Altered gene expression in the neurons during programmed cell death: identification of c-Jun as necessary for neuronal apoptosis. J Cell Biol 1994; 127: 1717-27.
19. Han L, Colicelli JA. Human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1. Mol Cell Biol 1995; 15: 1318-23.
20. Hamakawa H, Bao Y, Takarada M, Tanioka H. Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma. J Oral Pathol Med 1998; 27: 87-94.
21. Doi R, Makino T, Adachi H, Ryoke K, Ito H. Pre-operative radio-chemotherapy enhances apoptotic cell death in oral squamous cell carcinoma. J Oral Pathol Med 1998; 27: 382-7.
22. Sam JW, Takahashi S, Lippai I, Peisach J, Rousseau DL. Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA. J Biol Chem 1998; 273: 16090-7.
23. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-9.
24. Yang JJ. Mixed lineage kinase ZAK utilizing MKK7 and not MKK4 to activate the c-Jun N-terminal kinase and playing a role in the cell arrest. Biochem Biophys Res Commun 2002; 297: 105-10.
25. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucl Acids Res 1994; 22: 5506-7.
26. Hug H, Strand S, Grambihler A, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem 1997; 272: 28191-3.
27. Tai K-W, Chou MY, Hu CC, Yang JJ, Chang YC. Induction of apoptosis in KB cells by pingyangmycin. Oral Oncol 2000; 36: 242-7.
28. Chen Y-R, Tan T-H. The c-Jun N-terminal kinase pathway and apoptosis signaling. Int J Oncol 2000; 16: 651-62.
29. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/ERK pathway. Mol Cell Biol 1999; 19: 5308-15.
30. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinase on apoptosis. Science 1995; 270: 1326-31.
31. Hu WH, Johnson H, Shu HB. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274: 30603-10.
32. Guo Y-L, Kang B, Williamson JR. Inhibition of the expression of mitogen-activated protein phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-α in rat mesangial cells. J Biol Chem 1998; 273: 10362-6.
33. Simon C, Hick MJ, Nemechek AJ, et al. PD98059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 1999; 80: 1412-9.
34. Ghosh S, Munshi HG, Sen R, et al. Loss of adhesion-regulated proteinase production is correlated with invasive activity in oral squamous cell carcinoma. Cancer 2002; 95: 2524-33.
35. Mackeigen JP, Collins TS, Ting JPY. MEK inhibition enhances Paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275: 38953-6.
36. Shakibaei M, Schulze-Tanzil G, de Souza P, et al. Inhibition of mitogen-activated protein kinase kinase induces apoptosis of human chondrocytes. J Biol Chem 2001; 276: 13289-94.